Entresto Shines Brightly Among New Launches In India

Novartis’ Entresto has had a strong run in India, with two second brands in tow, while itraconazole and azilsartan therapies are among the other recent introductions that have gained traction in a competitive market.

Steps
ENTRESTO HAS MADE IMPRESSIVE GAINS IN INDIA

Heart failure therapy sacubitril/valsartan (Novartis AG’s Entresto) and cut-price versions of itraconazole (Johnson & Johnson’s Sporanox) and azilsartan (Takeda Pharmaceutical Co. Ltd.’s Edarbi) are among recent new introductions that have made an impressive start on the Indian market.

Entresto, which has seen galloping growth internationally, appears to have given Novartis a lot to cheer about in India. In...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip